HOUSTON - Bio-Path Holdings, Inc., , a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,.
HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a
Bio-Path Holdings, Inc Announces Closing of $1 2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its.